Quidel

News Release

Printer Friendly Version View printer-friendly version << Back
May 9, 2002 at 6:01 AM EDT

Quidel Announces Appointment of New Position for Vice President, Regulatory/Clinical and Quality Systems

SAN DIEGO, May 09, 2002 /PRNewsire-FirstCall via Comtex/ -- Quidel Corporation (Nasdaq: QDEL), a leading provider of rapid point-of-care (POC) diagnostic tests, today announced the appointment of Don A. Kennard to the newly created position of Vice President, Regulatory/Clinical and Quality Systems. Mr. Kennard has more than 20 years of professional experience in worldwide regulatory and quality systems as well as a successful track record of product approvals and inspections in pharmaceuticals and medical devices.

Mr. Kennard joins Quidel after ten years at Nobel Biocare, Inc., Gothenburg, Sweden, the largest manufacturer of dental implant products, where he served as Vice President R&D, Regulatory Affairs and Quality Assurance. During this time Mr. Kennard generated greater than 30% of annual sales by coordinating global R&D efforts, developed product innovations that increased market share positions >1% per year and served as a key member of the acquisition team that led to a profitable merger. Prior to joining Nobel Biocare, Inc., Mr. Kennard was Director of Regulatory Affairs and Quality Assurance at Allergan, Inc. and previously held the position of Director of Quality Control at McGaw Laboratories, Inc. He earned Bachelor of Science degrees in Microbiology and Chemistry from California State University in Long Beach.

As a key member of Quidel's operating committee, Mr. Kennard will be responsible for ensuring that all processes within Quidel are compliant to the current Quality Systems requirements, providing interpretation and direction to project teams on regulation requirements for target countries and for external relationships with worldwide regulatory agencies related to product approvals and quality systems.

"Don Kennard joins Quidel at a time when we are focusing on new technology development and global market penetration, as well as improving operational excellence in all functional areas," stated S. Wayne Kay, President and Chief Executive Officer of Quidel. "His proven record of meeting corporate objectives with product approvals and registrations, as well as his vast knowledge of worldwide regulatory and quality requirements, make him an invaluable member of our team."

About Quidel Corporation

Quidel Corporation, a worldwide company helping women and their families live healthy lives, discovers, develops, manufactures and markets rapid point- of-care diagnostic tests for detection of medical conditions and illnesses. These products provide accurate, rapid and cost-effective diagnostic information for acute and chronic conditions associated with women's health in areas such as reproduction and diseases of the elderly. Quidel also provides point-of-care diagnostics for infectious diseases, including influenza A and B, Strep throat, H. pylori infection, chlamydia, infectious mononucleosis and bacterial vaginosis. Quidel's products are sold to healthcare professionals for use in physician offices, clinical laboratories and pharmacies, and to consumers through organizations that provide private label, store brand products. These tests provide diagnostic information that enables rapid treatment and improves health outcomes, lowers costs and increases patient satisfaction. For more information, please visit Quidel's Web site at www.quidel.com .

This press release contains forward-looking statements regarding Quidel's future activities within the meaning of the federal securities laws. These forward-looking statements involve material risks and uncertainties. Many possible factors could affect the future results and performance of Quidel's business, such that actual results and performance may differ materially. If Quidel's products fail to perform as expected, or if there is lower consumer demand for these products than expected, Quidel's financial condition and operating results may be materially and adversely affected. Quidel's financial condition and operating results may also be materially and adversely affected by a number of other factors, including, without limitation, seasonality, adverse changes (both domestically and internationally) in competitive and economic conditions, actions by the Company's distributors, manufacturing and production delays or difficulties and adverse actions or delays in product reviews by the FDA. Please see the discussion of these and other factors in Quidel's annual report on Form 10-K and subsequent quarterly reports on Form 10-Q.

SOURCE Quidel Corporation

CONTACT:
Martin Halsall, mhalsall@lhai.com, or Bruce Voss,
bvoss@lhai.com, both of Lippert